Import Diabetes Therapeutic Device — Buy in Bulk from Supplier in China

The Diabetes therapeutic device offered by Beijing Golden Huahan New Tech. Co., Ltd. incorporates advanced biosensing technology that delivers real‑time glucose readings, integrates directly with mobile applications for data tracking, and provides audible or visual alerts when glucose levels approach critical thresholds. The unit is designed with a compact, portable housing that fits comfortably in a pocket or on a bedside table. The listing highlights a user‑friendly interface that simplifies daily monitoring for both patients and clinicians. All features are presented as part of a single, handheld system aimed at early detection of diabetic conditions.

In the broader medical‑device market, continuous glucose monitors typically employ enzymatic electrochemical sensors and require calibration within a defined glucose range. Devices of this class are commonly powered by rechargeable lithium‑ion batteries and must meet accuracy standards of ±5 % according to ISO 15197. The Beijing supplier notes that the device conforms to ISO and CE guidelines, which are standard certifications for health‑care equipment exported from China. Typical supporting accessories include a charging cable and a protective case, both of which are often supplied in the retail package.

Healthcare providers, diabetes clinics, and individuals managing the condition are the primary buyers of this technology. The supplier indicates that order quantities can be adjusted to suit both small clinics and larger distribution networks, and that shipping terms such as FOB or CIF are available upon request. Buyers are advised to confirm the presence of ISO and CE documentation before finalising a purchase. Payment methods and detailed lead‑time estimates are not disclosed in the listing and should be negotiated directly with the supplier.

Beijing Golden Huahan New Tech. Co., Ltd. is registered at FL7, Block B, Yonghe Plaza, Beijing 100007, Dongcheng, China. The company is listed as an imported supplier with a harbor trust tier, indicating that it participates in cross‑border trade through major Chinese ports. Current platform metrics show a response rate of 0 % and no recorded average response time, suggesting that inquiries may require follow‑up through alternative contact channels.

The firm markets the Diabetes therapeutic device as part of its health‑technology portfolio, emphasizing the integration of biosensing and mobile data management. No additional corporate history, employee count, or client list is provided in the source data, and the listing does not specify any other product lines or manufacturing facilities. All claims are limited to the information supplied in the product description.